Such effect was further enhanced by a concomitant treatment with the ADORA1 agonist, thus suggesting that ADORA1 represents a therapeutic target to modulate neuroinflammation in MS and other demyelinating diseases [43]. Here, ADORA1 is linked to myeloid sarcoma.